U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Substance Class Protein
Created
by admin
on Mon Mar 31 21:31:38 GMT 2025
Edited
by admin
on Mon Mar 31 21:31:38 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG2A
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
716FQ5REVO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ASCRINVACUMAB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
PF-03446962
Preferred Name English
ASCRINVACUMAB [USAN]
Common Name English
IMMUNOGLOBULIN G2, ANTI-(HUMAN ACTIVIN RECEPTOR-LIKE KINASE 1) (HUMAN MONOCLONAL PF-03446962 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL PF-03446962 LIGHT CHAIN, DIMER
Common Name English
ascrinvacumab [INN]
Common Name English
GT-90001
Code English
GT90001
Code English
PF03446962
Code English
Ascrinvacumab [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C20401
Created by admin on Mon Mar 31 21:31:38 GMT 2025 , Edited by admin on Mon Mar 31 21:31:38 GMT 2025
NCI_THESAURUS C129822
Created by admin on Mon Mar 31 21:31:38 GMT 2025 , Edited by admin on Mon Mar 31 21:31:38 GMT 2025
Code System Code Type Description
FDA UNII
716FQ5REVO
Created by admin on Mon Mar 31 21:31:38 GMT 2025 , Edited by admin on Mon Mar 31 21:31:38 GMT 2025
PRIMARY
DRUG BANK
DB12261
Created by admin on Mon Mar 31 21:31:38 GMT 2025 , Edited by admin on Mon Mar 31 21:31:38 GMT 2025
PRIMARY
USAN
BC-56
Created by admin on Mon Mar 31 21:31:38 GMT 2025 , Edited by admin on Mon Mar 31 21:31:38 GMT 2025
PRIMARY
SMS_ID
100000167442
Created by admin on Mon Mar 31 21:31:38 GMT 2025 , Edited by admin on Mon Mar 31 21:31:38 GMT 2025
PRIMARY
NCI_THESAURUS
C91073
Created by admin on Mon Mar 31 21:31:38 GMT 2025 , Edited by admin on Mon Mar 31 21:31:38 GMT 2025
PRIMARY
CAS
1463459-96-2
Created by admin on Mon Mar 31 21:31:38 GMT 2025 , Edited by admin on Mon Mar 31 21:31:38 GMT 2025
PRIMARY
INN
10106
Created by admin on Mon Mar 31 21:31:38 GMT 2025 , Edited by admin on Mon Mar 31 21:31:38 GMT 2025
PRIMARY
ChEMBL
CHEMBL2109295
Created by admin on Mon Mar 31 21:31:38 GMT 2025 , Edited by admin on Mon Mar 31 21:31:38 GMT 2025
PRIMARY
EVMPD
SUB181657
Created by admin on Mon Mar 31 21:31:38 GMT 2025 , Edited by admin on Mon Mar 31 21:31:38 GMT 2025
PRIMARY
WIKIPEDIA
Ascrinvacumab
Created by admin on Mon Mar 31 21:31:38 GMT 2025 , Edited by admin on Mon Mar 31 21:31:38 GMT 2025
PRIMARY
From To
1_22 1_97
2_22 2_97
3_23 3_89
4_23 4_89
1_132 3_215
2_132 4_215
3_135 3_195
4_135 4_195
1_145 1_201
2_145 2_201
1_220 2_220
1_221 2_221
1_224 2_224
1_227 2_227
1_258 1_318
2_258 2_318
1_364 1_422
2_364 2_422
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_294
N 2_294
Related Record Type Details
ACTIVIN RECEPTOR TYPE-1
TARGET -> INHIBITOR
Related Record Type Details
ASCRINVACUMAB
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO ACID SUBSTITUTION [1_1] [2_1] PIDOLIC ACID SZB83O1W42
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966